摘要: The human genome comprises 57 putatively functional, protein-coding cytochrome P450 (CYP) genes that are grouped according to their sequence similarity into 18 families and 44 subfamilies. Approximately one dozen CYP isozymes of 1, 2, 3 mainly responsible for the metabolism drugs other xenobiotics. Large interindividual variability these enzymes, which both genetic nongenetic factors contribute, is an important determinant drug pharmacokinetics response. This chapter summarizes clinical, toxicological relevance polymorphism, affects all drug-metabolizing CYPs, but a very different extent. Keywords: cytochrome P450; drug metabolism; pharmacogenetics; pharmacogenomics; polymorphism
sci-hub.se 参考文章(227)
M A Perera, R K Thirumaran, N J Cox, S Hanauer, S Das, C Brimer-Cline, V Lamba, E G Schuetz, M J Ratain, A Di Rienzo, Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics Journal. ,vol. 9, pp. 49- 60 ,(2009) , 10.1038/TPJ.2008.13
L Bertilsson, Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clinical Pharmacology & Therapeutics. ,vol. 82, pp. 606- 609 ,(2007) , 10.1038/SJ.CLPT.6100358
Patricia A. Harper, David S. Riddick, Allan B. Okey, Regulating the regulator: factors that control levels and activity of the aryl hydrocarbon receptor. Biochemical Pharmacology. ,vol. 72, pp. 267- 279 ,(2006) , 10.1016/J.BCP.2006.01.007
B Wang, S-F Zhou, None, Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development Current Medicinal Chemistry. ,vol. 16, pp. 4066- 4218 ,(2009) , 10.2174/092986709789378198
Julia di Iulio, Aurélie Fayet, Mona Arab-Alameddine, Margalida Rotger, Rubin Lubomirov, Matthias Cavassini, Hansjakob Furrer, Huldrych F. Günthard, Sara Colombo, Chantal Csajka, Chin B. Eap, Laurent A. Decosterd, Amalio Telenti, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function Pharmacogenetics and Genomics. ,vol. 19, pp. 300- 309 ,(2009) , 10.1097/FPC.0B013E328328D577
R FUX, K MORIKE, A PROHMER, U DELABAR, M SCHWAB, E SCHAEFFELER, G LORENZ, C GLEITER, M EICHELBAUM, K KIVISTO, Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study Clinical Pharmacology & Therapeutics. ,vol. 78, pp. 378- 387 ,(2005) , 10.1016/J.CLPT.2005.07.004
Chih-Ching Yeh, Fung-Chang Sung, Li-Tang Kuo, Wan-Ping Hsu, Hsiang-Yu Chu, Polymorphisms of cytochrome P450 1A1, cigarette smoking and risk of coronary artery disease. Mutation Research. ,vol. 667, pp. 77- 81 ,(2009) , 10.1016/J.MRFMMM.2009.04.001
Jill C Mwenifumbo, Rachel F Tyndale, Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics. ,vol. 8, pp. 1385- 1402 ,(2007) , 10.2217/14622416.8.10.1385
T Saussele, O Burk, J K Blievernicht, K Klein, A Nussler, N Nussler, J G Hengstler, M Eichelbaum, M Schwab, U M Zanger, Selective Induction of Human Hepatic Cytochromes P450 2B6 and 3A4 by Metamizole Clinical Pharmacology & Therapeutics. ,vol. 82, pp. 265- 274 ,(2007) , 10.1038/SJ.CLPT.6100138
Nikolaos A. Patsopoulos, Evangelia E. Ntzani, Elias Zintzaras, John P.A. Ioannidis, CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenetics and Genomics. ,vol. 15, pp. 151- 158 ,(2005) , 10.1097/01213011-200503000-00003